Logo for Vivesto

Vivesto Investor Relations Material

Latest events

Logo for Vivesto

R&D Update

Vivesto
Logo for Vivesto

R&D Update

26 Mar, 2024
Logo for Vivesto

Q3 23/24

22 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Vivesto

Access all reports
Segment Data
Access more data
Net sales by
Source
Sales of goods
Expenses by
Financials
Vivesto AB develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. The company offers XRP988/Apealea/Doxophos that is a drug consisting of doxorubicin encapsulated in an oil-based carrier system for injection; and Paclical/Apalutamide that is an oral formulation of a pure antiandrogen. It serves various markets through third party distributors. The company was formerly known as Oasmia Pharmaceutical AB and changed its name to Vivesto AB in March 2022. The company was founded in 1988 and is headquartered in Solna, Sweden.